Why the study?
It was largely unknown whether the presence of distinct cerebrovascular risk factors alters the prognosis of patients with brain metastases.
Does the presence of diabetes mellitus reduce overall survival in patients with brain metastases treated with radiotherapy?
Does the presence of diabetes mellitus reduce overall survival in patients with brain metastases treated with radiotherapy?
Diabetes mellitus is a strong independent negative prognostic factor for overall survival in patients with brain metastases undergoing radiotherapy.
Answers are grounded in this paper and cite their sources.
DM may worsen BM survival after radiotherapy; leaves open whether glycemic control modifies prognosis.
Background: Brain metastases (BM) cause relevant morbidity and mortality in cancer patients. The presence of cerebrovascular diseases can alter the tumor microenvironment, cellular proliferation and treatment resistance. However, it is largely unknown if the presence of distinct cerebrovascular risk factors may alter the prognosis of patients with BM. Methods: Patients admitted for the radiotherapy of BM at a large tertiary cancer center were included. Patient and survival data, including cerebrovascular risk factors (diabetes mellitus (DM), smoking, arterial hypertension, peripheral arterial occlusive disease, hypercholesterolemia and smoking) were recorded. Results: 203 patients were included. Patients with DM (n = 39) had significantly shorter overall survival (OS) (HR 1.75 (1.20–2.56), p = 0.003, log-rank). Other vascular comorbidities were not associated with differences in OS. DM remained prognostically significant in the multivariate Cox regression including established prognostic factors (HR 1.92 (1.20–3.06), p = 0.006). Furthermore, subgroup analyses revealed a prognostic role of DM in patients with non-small cell lung cancer, both in univariate (HR 1.68 (0.97–2.93), p = 0.066) and multivariate analysis (HR 2.73 (1.33–5.63), p = 0.006), and a trend in melanoma patients. Conclusion: DM is associated with reduced survival in patients with BM. Further research is necessary to better understand the molecular mechanisms and therapeutic implications of this important interaction.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: